$5.63 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 143 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| OMIC | New | SINGULAR GENOMICS SYSTEMS IN | $250,398,000 | – | 9,112,019 | +100.0% | 4.45% | – |
| CMAX | New | CAREMAX INC | $216,446,000 | – | 16,778,750 | +100.0% | 3.84% | – |
| New | GLAUKOS CORPnote 2.750% 6/1 | $153,534,000 | – | 90,000,000 | +100.0% | 2.73% | – | |
| New | NATERA INCnote 2.250% 5/0 | $136,309,000 | – | 45,000,000 | +100.0% | 2.42% | – | |
| New | ENVISTA HOLDINGS CORPORATIONnote 2.375% 6/0 | $112,018,000 | – | 52,500,000 | +100.0% | 1.99% | – | |
| New | NUVASIVE INCnote 1.000% 6/0 | $101,298,000 | – | 96,966,000 | +100.0% | 1.80% | – | |
| New | INSMED INCnote 0.750% 6/0 | $55,522,000 | – | 50,000,000 | +100.0% | 0.99% | – | |
| QDEL | New | QUIDEL CORP | $52,429,000 | – | 409,219 | +100.0% | 0.93% | – |
| GLPG | New | GALAPAGOS NVspon adr | $45,261,000 | – | 657,005 | +100.0% | 0.80% | – |
| HOWL | New | WEREWOLF THERAPEUTICS INC | $44,521,000 | – | 2,552,787 | +100.0% | 0.79% | – |
| KURA | New | KURA ONCOLOGY INC | $37,405,000 | – | 1,794,000 | +100.0% | 0.66% | – |
| New | HEALTH CATALYST INCnote 2.500% 4/1 | $28,740,000 | – | 15,000,000 | +100.0% | 0.51% | – | |
| GRPH | New | GRAPHITE BIO INC | $27,851,000 | – | 906,308 | +100.0% | 0.50% | – |
| CGEM | New | CULLINAN ONCOLOGY INC | $26,883,000 | – | 1,044,000 | +100.0% | 0.48% | – |
| AVAH | New | AVEANNA HEALTHCARE HLDGS INC | $24,740,000 | – | 2,000,000 | +100.0% | 0.44% | – |
| BHG | New | BRIGHT HEALTH GROUP INC | $24,024,000 | – | 1,400,000 | +100.0% | 0.43% | – |
| SPRB | New | SPRUCE BIOSCIENCES INC | $22,946,000 | – | 2,046,958 | +100.0% | 0.41% | – |
| MAACU | New | MONTES ARCHIMEDES ACQUISITIOunit 09/30/2025 | $21,320,000 | – | 2,000,000 | +100.0% | 0.38% | – |
| OM | New | OUTSET MED INC | $20,023,000 | – | 400,622 | +100.0% | 0.36% | – |
| DAWN | New | DAY ONE BIOPHARMACEUTICALS I | $18,648,000 | – | 818,980 | +100.0% | 0.33% | – |
| STXS | New | STEREOTAXIS INC | $17,767,000 | – | 1,843,000 | +100.0% | 0.32% | – |
| JANX | New | JANUX THERAPEUTICS INC | $17,465,000 | – | 700,000 | +100.0% | 0.31% | – |
| QSI | New | QUANTUM SI INC | $17,164,000 | – | 1,400,000 | +100.0% | 0.30% | – |
| AVTE | New | AEROVATE THERAPEUTICS INC | $16,307,000 | – | 714,285 | +100.0% | 0.29% | – |
| PRVA | New | PRIVIA HEALTH GROUP INC | $13,311,000 | – | 300,000 | +100.0% | 0.24% | – |
| CNVY | New | CONVEY HLDG PARENT INC | $12,518,000 | – | 1,100,000 | +100.0% | 0.22% | – |
| AGL | New | AGILON HEALTH INC | $12,171,000 | – | 300,000 | +100.0% | 0.22% | – |
| GHRS | New | GH RESEARCH PLCordinary shares | $12,069,000 | – | 555,416 | +100.0% | 0.21% | – |
| CVRX | New | CVRX INC | $11,200,000 | – | 400,000 | +100.0% | 0.20% | – |
| LFST | New | LIFESTANCE HEALTH GROUP INC | $11,144,000 | – | 400,000 | +100.0% | 0.20% | – |
| RPHM | New | RENEO PHARMACEUTICALS INC | $7,924,000 | – | 849,300 | +100.0% | 0.14% | – |
| GLUE | New | MONTE ROSA THERAPEUTICS INC | $7,945,000 | – | 350,000 | +100.0% | 0.14% | – |
| TALK | New | TALKSPACE INC | $6,233,000 | – | 750,000 | +100.0% | 0.11% | – |
| INSM | New | INSMED INC | $5,692,000 | – | 200,000 | +100.0% | 0.10% | – |
| BMEA | New | BIOMEA FUSION INC | $3,878,000 | – | 248,447 | +100.0% | 0.07% | – |
| CMAXW | New | CAREMAX INC*w exp 06/08/202 | $3,172,000 | – | 672,000 | +100.0% | 0.06% | – |
| QSIAW | New | QUANTUM SI INC*w exp 06/10/202 | $1,253,000 | – | 333,333 | +100.0% | 0.02% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
| 13F-HR | 2023-11-14 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.